Juliette Peyronnet is the U.S. General Manager at Alice & Bob, leading the company’s commercialization strategy in the United States. With over eight years of experience in bringing deep-tech products to market, she has a strong background in go-to-market strategy and business development. Juliette holds a Master of Science in Photonics and previously advised the French government on GTM strategy in North America. Before joining Alice & Bob, she was a Business Development Lead at Xanadu, where she played a key role in advancing quantum technology adoption.

Raffaele Santagati is a distinguished quantum computing scientist with extensive expertise in quantum technologies, photonics, and computational physics. With a PhD in Quantum Photonics and Quantum Computing from the University of Bristol, he has built a career at the forefront of quantum research, industry innovation, and scientific publishing. Currently, Raffaele serves as a Quantum Computing Scientist at Boehringer Ingelheim, where he explores the application of quantum computing in pharmaceutical research and drug discovery. In addition, he holds the role of Editor at Springer Nature, overseeing scholarly content related to quantum computing and emerging quantum technologies. Prior to his industry roles, Raffaele spent over eight years at the University of Bristol, where he was a Senior Research Associate at the Quantum Engineering Technology Labs (QETLabs) and a Postdoctoral Research Associate at the Centre for Quantum Photonics. His research focused on developing scalable quantum photonic technologies, quantum information processing, and experimental quantum mechanics. During this time, he also worked as a quantum technologies consultant, advising multinational corporations on the strategic implications of quantum computing and how to mitigate risks while leveraging emerging opportunities. Beyond his research, Raffaele has contributed to academia as a teaching assistant in Classical Physics and Quantum Mechanics at the University of Bristol. His early career includes research positions at EuroImaging, the European Synchrotron Radiation Facility (ESRF), and STARFLAG CNR INFM, where he worked on projects related to OCT imaging, inelastic X-ray scattering spectrometry, and complex system modeling. Raffaele holds a Doctor of Philosophy (PhD) in Quantum Photonics and Quantum Computing from the University of Bristol and a Master of Science in Physics (Laurea Specialistica) from Sapienza Università di Roma. With a strong foundation in quantum mechanics, photonics, and computational physics, Raffaele continues to push the boundaries of quantum computing research, bridging the gap between theoretical advancements and real-world applications in industry and academia.

Holly Stemp is a postdoctoral researcher at the Massachusetts Institute of Technology (MIT), specializing in hybrid spin/superconducting qubit architectures. Her research focuses on advancing quantum computing technologies by integrating superconducting and spin-based qubit systems to improve scalability and coherence times. Prior to joining MIT, Holly completed her PhD at UNSW in Sydney, where she worked on donor atom spin qubits for quantum computation. She holds an MPhys in Physics from the University of Surrey, graduating with First Class Honours. Her research experience spans multiple leading institutions, including Oak Ridge National Laboratory, where she contributed to quantum computing projects, and the National Physical Laboratory (NPL), where she investigated the International Temperature Scale of 1990 (ITS-90). Passionate about driving diversity in STEM, Holly actively supports initiatives that encourage more women and girls to pursue careers in physics and quantum technology.

Gabriela Cimpan holds a PhD in Chemistry and has spent the first years of her career as a university lecturer and research scientist. She then transitioned in technical sales and business development, focusing on high end scientific software over the last 20 years, with a focus on chemistry and life sciences. In 2021, Gabriela joined the business development team at Cambridge Quantum Computing, now Quantinuum, continuing to work with customers and partners at the forefront of scientific innovation.

Ms. Dolcetti boasts over 15 years of multifaceted expertise in Global Health Tech, Digital Innovation, and Artificial Intelligence, with a background spanning startups, Fortune 500 companies, academia, and management consulting, including a tenure at Boston Consulting Group. Specializing in life sciences, she excels in corporate strategy, private equity/venture capital, partnerships, and commercialization, showcasing a knack for successful product launches. Her subject matter expertise spans precision medicine, diagnostics, genomics, oncology, and the integration of AI, informatics, data analytics, cloud infrastructure, and SaaS solutions. A seasoned professional in navigating the convergence of healthcare and technology, Sara brings strategic acumen to the evolving landscape of digital health and medical devices. Continuously staying abreast of industry trends, she is a driving force committed to advancing healthcare through innovative technological solutions.

Johannes has spent 15 years in the Data, AI, Quantum Tech, and Intrapreneurship space. Prior to Diffraqtion, he was an Executive Director at Novartis, heading the largest Data & AI transformation in the industry. He was also a researcher at MIT and the Center for Quantum Networks, a lecturer in AI, and a managing consultant at a Big Four. He’s an MIT Sloan Fellows MBA, Oxford, and Uni Frankfurt graduate with a focus on AI, Quantum Technologies and entrepreneurship for deeptech commercialization.

Holly Stemp is a postdoctoral researcher at the Massachusetts Institute of Technology (MIT), specializing in hybrid spin/superconducting qubit architectures. Her research focuses on advancing quantum computing technologies by integrating superconducting and spin-based qubit systems to improve scalability and coherence times. Prior to joining MIT, Holly completed her PhD at UNSW in Sydney, where she worked on donor atom spin qubits for quantum computation. She holds an MPhys in Physics from the University of Surrey, graduating with First Class Honours. Her research experience spans multiple leading institutions, including Oak Ridge National Laboratory, where she contributed to quantum computing projects, and the National Physical Laboratory (NPL), where she investigated the International Temperature Scale of 1990 (ITS-90). Passionate about driving diversity in STEM, Holly actively supports initiatives that encourage more women and girls to pursue careers in physics and quantum technology.

Huafeng Xu, Ph.D., is the Founder and CEO of Atommap, a New York-based seed-stage company transforming drug discovery through advanced computational methods. Atommap’s proprietary platform harnesses biomolecular dynamics to deliver therapeutic molecules that reprogram protein function. Since its founding in 2023, Atommap has partnered with 8 companies in their discovery projects and has on its own developed first-in-class molecules addressing a challenging oncological target. Huafeng previously served as Chief Technology Officer of Silicon Therapeutics, which Roivant acquired in 2021, then as CTO of Roivant Discovery before launching Atommap with his co-founders. Over his 25-year career as a chemist and computer scientist, he has developed the methods and software for molecular dynamics simulations and free energy calculations that are now widely used in the pharmaceutical industry, and he has pioneered the industrial application of computation-driven drug design. His publications have garnered over 10,000 citations. He earned his Bachelor of Science from Peking University and his M.S. and Ph. D. from Columbia University, and was a visiting postdoctoral scholar in UC San Francisco. In his spare time, Huafeng enjoys wine and solving math problems, sometimes simultaneously.

Ricardo Gaviria is a Scientific Solution Engineer at Roche, where he focuses on bridging the gap between scientific needs and technical solutions within the Data & Analytics department of pRED. Having worked in numerous areas (Automotive industry, Lab Automation and Pharma) he considers himself a "jack of all trades, master of none". His main areas of focus include acting as Product Owner of an automated screening cascade tool used within Roches discovery projects, and understanding how to make better sense of the operational data available in the organization.

Fernanda Foertter is currently the Director of Developer Relations at Voltron Data. She previously held roles as the Senior Scientific Consultant for BioTeam and GPU Developer Advocate for Bioinformatics at NVIDIA in the Healthcare group where she fostered an emerging community in AI and GPU computing. Before NVIDIA, Foertter held roles as an HPC Data Scientist in the Biomedical Sciences and Engineering group and was an HPC Programmer and Training Coordinator at the Oak Ridge National Lab's Leadership Computing Facility. She participated in the CORAL project that selected Summit as the next supercomputer to replace Titan, was co-PI of Kokkos Exascale Computing Project, served in OpenACC and OpenMP language standards, and is the “inventor” of the GPU Hackathon training series. Other interests include the intersection of HPC and AI, facilitating data integration workflows, and productivity in scientific application development.

Ryan Chandler is a Knowledge Graph Engineer at AbbVie. He holds a PhD in Informatics from the University of Illinois, with a focus on the linguistic and cognitive aspects of knowledge representation. Ryan has dedicated his career to understanding what it means for computers to effectively "know" information. His work at AbbVie centers on developing semantic knowledge graphs and analytic solutions for research and development. He enables research scientists to explore and uncover meaningful insights from large bodies of previously unrelated knowledge and data sources.